Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434969 | 1.00 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL430047 | 0.91 | CA1 (0.58) | CA4LTA4HCA12CA1CA2 | |
| SCHEMBL774134 | 0.87 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8784660 | 0.87 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| Bromide SCHEMBL31164184 | 0.85 | CA4 (0.52) | CA4LTA4HKIF11KCNH2CA12 | |
| Hydrochloric Acid SCHEMBL30389842 | 0.85 | CA4 (0.52) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8728589 | 0.83 | KIF11 (0.56) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL3932304 | 0.83 | CA4 (0.50) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL21738735 | 0.83 | KIF11 (0.56) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL19620174 | 0.83 | CA4 (0.50) | CA4LTA4HKIF11KCNH2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236633-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | Roche Sequencing Solutions, Inc. (US) | 2025-07-24 | — | — | US | claimed |
| EP-4499655-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | F. Hoffmann-La Roche AG (CH) | 2025-02-05 | — | — | EP | claimed |
| WO-2023186842-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-10-05 | — | — | WO | claimed |
| CN-113286803-A | S-antigen transport inhibiting oligonucleotide polymers and methods | 阿里戈斯治疗公司 | 2021-08-20 | — | — | CN | claimed |
| EP-3853240-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | Aligos Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | claimed |
| US-20210189392-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | claimed |
| WO-2021119325-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| WO-2020119205-A1 | RADIOACTIVE FLUORINE-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD THEREFOR | 上海健康医学院 | 2020-06-18 | — | — | WO | claimed |
| US-20200147124-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2020-05-14 | — | — | US | claimed |
| CN-109705124-A | A kind of labeled with radioactive fluorine Larotrectinib compound and preparation method thereof | 上海健康医学院 | 2019-05-03 | — | — | CN | claimed |
| US-20150099864-A1 | PREPARATION OF ORGANOPHOSPHATE PEPTIDE ADDUCTS | BATTELLE MEMORIAL INSTITUTE | 2015-04-09 | — | — | US | claimed |
| WO-2005058246-A2 | METHOD FOR PREPARING RADIOLABELED THYMIDINE | MOLECULAR TECHNOLOGIES, INC. (US) | 2005-06-30 | — | — | WO | claimed |
| US-20050131224-A1 | Method for preparing radiolabeled thymidine | CTI PET SYSTEMS, INC. | 2005-06-16 | — | — | US | claimed |
| US-20030069414-A1 | Urea nucleosides as therapeutic and diagnostic agents | GILEAD SCIENCES, INC. | 2003-04-10 | — | — | US | claimed |
| US-6414137-B1 | Selective solvent extraction for the purification of protected nucleosides | ALLIEDSIGNAL INC. | 2002-07-02 | — | — | US | claimed |
| EP-1140957-A1 | SELECTIVE SOLVENT EXTRACTION FOR THE PURIFICATION OF PROTECTED NUCLEOSIDES | AlliedSignal Inc. (US) | 2001-10-10 | — | — | EP | claimed |
| US-6143882-A | REACTING A NUCLEOSIDE STARTING MATERIAL CONTAINING A LEAVING GROUP WITH A VINYLSTANNE OF DEFINED FORMULA AND CARBON MONOXIDE IN PRESENCE OF A PALLADIUM CATALYST TO FORM AN ENE-ONE INTERMEDIATE, REACTING WITH AN AMINE, AND ISOLATING | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-07 | — | — | US | claimed |
| WO-2000039138-A1 | SELECTIVE SOLVENT EXTRACTION FOR THE PURIFICATION OF PROTECTED NUCLEOSIDES | ALLIEDSIGNAL INC. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-1997035868-A9 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | — | 1997-12-24 | — | — | WO | claimed |
| WO-1997035868-A1 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131224-A1 | Method for preparing radiolabeled thymidine | TYMP, TYMS, DUT | CA4 3875/4885LTA4H 1482/4885KIF11 650/4885 |
| US-20200147124-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | CA4 3693/4885LTA4H 4182/4885KIF11 3088/4885 |
| US-20030069414-A1 | Urea nucleosides as therapeutic and diagnostic agents | NUDT1, ADAR, DUT | CA4 3774/4885LTA4H 3665/4885KIF11 3839/4885 |
| US-20250236633-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | PARG, PPA1, PGM2 | CA4 1762/4885LTA4H 3409/4885KIF11 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.